An Efficacy and Safety Study of DFN-02

Inclusion Criteria:

1. A history of episodic migraine who experience an average of 2 to 8 migraine attacks
per month for at least the past 12 months, with no more than 14 headache days per
month, and with 48 hours of headache free time between migraine headaches

2. Patients who have migraine with or without aura. If migraine with aura, the aura
cannot last longer than 60 minutes.

3. Patients who are willing and able to:

1. Evaluate and record pain, migraine symptoms, and study medication effectiveness
information in real-time using an eDiary for the duration of the study;

2. Record each instance of the use of study medication and rescue medication in a
patient eDiary in real-time for the duration of the study;

3. Comply with all other study procedures and scheduling requirements.

Exclusion Criteria:

1. Minors, even if they are in the specified study age range

2. Medication overuse:

1. Opioids ≥ 10 days during the 90 days prior to screening

2. Combination medications (e.g., Fiorinal®) ≥ 10 days during the 90 days prior to
screening (only applies if combination medication contains an opioid and/or
barbiturate)

3. Nonsteroidal Anti-inflammatory Drugs or other simple medications ˃ 14 days a
month during the 90 days prior to screening

4. Triptans or ergots ≥ 10 days a month during the 90 days prior to screening

3. Treated with onabotulinumtoxinA (Botox®) or other botulinum toxin treatment within 4
months prior to screening for migraine prophylaxis (patients who were treated with
same for cosmetic purposes may be allowed on a case-by-case basis after approval from
the Medical Monitor)

4. A history of or current neurological or psychiatric impairment, or cognitive
dysfunction that, in the opinion of the Investigator, would compromise data collection

5. Use of antipsychotics at least 15 days prior to randomization

6. Patients who received treatment with an investigational drug or device within 30 days
prior to randomization, or within 3 months if associated with central nervous system

7. Patients who participated in a central nervous system clinical trial within 3 months
prior to randomization

8. Patients who test positive for human immunodeficiency virus (HIV), hepatitis B surface
antigen (HBsAg), or hepatitis C virus (HCV) antibody serology testing

9. Patients who are employees or immediate relatives of the employees of the Sponsor, any
of its affiliates or partners, or of the clinical study research site